About this document

See Full Prescribing Information For Complete Boxed Warning by harpreetboxer99 is a document available to read on EtoBox.

OZEMPIC (semaglutide) is a GLP-1 receptor agonist approved for improving glycemic control in adults with type 2 diabetes, but is contraindicated in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It carries warnings for potential risks such as thyroid C-cell tumors, pancreatitis, and diabetic retinopathy complications. The recommended starting dosage is 0.25 mg once weekly, increasing to a maximum of 1 mg weekly as needed, with specific administration

Author

harpreetboxer99

Language

EN